The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis
Pooled result · Disease recurrenceResult — go to the resultRelative risk 0.78 95% CI 0.67–0.90Authors' conclusion
Using antiresorptive agents early in patients with breast cancer receiving adjuvant endocrine therapy may provide additional benefits in risk reduction of recurrence, but there is a potential risk of ONJ.
Study context
- Population
- Patients with primary (early) breast cancer receiving adjuvant endocrine therapy
- Comparison
- Antiresorptive agents vs control
- Outcome
- Disease recurrence
Pooled result
As reported in the abstract
Relative risk
0.78
95% CI 0.67–0.90
Antiresorptive agentsvs Control
RR 0.78 (95% CI 0.67–0.90)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Locoregional recurrenceAntiresorptive agentsvs Control | 0.69 (0.49–0.95) | |
| 0.512Relative risk (log scale) |
Endocrine therapy resistance
- Early use of antiresorptive agents beneficial for secondary, not primary, endocrine therapy resistance
Subgroup: bisphosphonates
- Bisphosphonates might have profound clinical benefits but also increased osteonecrosis of the jaw (ONJ)
Network meta-analysis: early vs delayed use or placebo
- Network meta-analysis supported clinical effects of early antiresorptive use vs delayed use or placebo
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| Osteonecrosis of the jaw (ONJ)Antiresorptive agentsvs Control | 3.29 (1.12–9.68) | |
| 0.10.31310Relative risk (log scale) |
Arthralgia
- Insignificant difference in arthralgia
Original publication
The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis. J Clin Endocrinol Metab. Published 12 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →